Prolonged response after TPO-RA discontinuation in primary ITP: results of a prospective multicenter study
Blood · 09.03.2023
DOI: 10.1182/blood.2022018665 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Blood, online erschienen am 09.03.2023. Verfasst von Stéphanie Guillet und 41 weiteren Autor:innen. Beteiligte Einrichtung: Service de Médecine Interne, Centre National de Référence des Cytopénies Auto-Immunes de l'Adulte, Henri Mondor Hôpital, Fédération Hospitalo-Univers…. Hauptthemen laut MEDLINE: Purpura, Thrombocytopenic, Idiopathic, Thrombocytopenia. Die Arbeit wurde bisher 15-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Sustained response off-treatment (SROT) after thrombopoietin receptor agonist (TPO-RA) discontinuation has been reported in ITP. This prospective multicenter interventional study enrolled adults with persistent or chronic primary ITP and complete response on TPO-RAs. The primary endpoint was the proportion of patients achieving SROT (platelet count > 30x109/L and no bleeding) at W24 with no other ITP-specific medications. Secondary endpoints included the proportion of sustained complete response off-treatment (SCROT, platelet count > 100x109/L and no bleeding) and SROT at W52, bleeding events, and pattern of response to a new course of TPO-RAs. We included 48 patients with median (IQR) age 58.5 years (41-73.5); 30/48 (63%) had chronic ITP at TPO-RA initiation. In the intention-to-treat analysis, 27/48 (56.2%, 95% CI, 41.2-70.5) achieved SROT; 15/48 (31.3%; 95% CI, 18.9-44.5) achieved SCROT at W24, and 25/48 (52.1%; 95% CI, 37.2-66.7) achieved respectively SROT and 14/48 (29.2%; 95% CI, 17.2-42.3) SCROT at W52. No severe bleeding episode occurred in patients who relapsed. Among patients re-challenged with TPO-RA, 11/12 achieved CR. We found no significant clinical predictors of SROT at W24. Single-cell RNA-seq revealed enrichment of a "TNFα signaling via NF-κB" signature in CD8+ T cells of patients with no sustained response after TPO-RA discontinuation, which was further confirmed by a significant overexpression of CD69 on CD8+ T cells at baseline in these patients as compared with those achieving SCROT/SROT. Our results strongly support a strategy based of progressive tapering and discontinuation of TPO-RAs for patients with chronic ITP who achieved a stable CR on treatment. Clinical trial number: NCT03119974
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Service de Médecine Interne, Centre National de Référence des Cytopénies Auto-Immunes de l'Adulte, Henri Mondor Hôpital, Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErs, Assistance Publiq…
- INSERM U1151/CNRS UMS 8253, Institut Necker Enfants Malades, ATIP-Avenir Team AI2B, Université de Paris Cité, Université Paris-Est Créteil (UPEC), Créteil, France.
- INSERM UMR U1163,Imagine Institute, Laboratory of Immunogenetics of Pediatric Autoimmune Diseases, Université de Paris Cité, Paris, France.
- INSERM U955, Équipe 2, Université Paris-Est Créteil (UPEC), Créteil, France.
- Unité de Recherche Clinique (Mondor), AP-HP, Henri Mondor Hôpitaux Universitaires, Créteil, France.
- INSERM, Institut Mondor de Recherche Biomédicale, Équipe Clinical Epidemiology and Ageing, UPEC, Créteil, France.
ORCID-Profile: Etienne Crickx, Pascal Chappert, Jean-François Viallard, Nicolas Noel, Nihal Martis, Jean-Christophe Lega, Mickael Menager, Sophie Hue, Florence Canoui-Poitrine, Matthieu Mahévas
Zitieren
APA
Guillet, S., Crickx, E., Azzaoui, I., Chappert, P., Boutin, E., Viallard, J. F., Rivière, E., Gobert, D., Galicier, L., Malphettes, M., Cheze, S., Lefrere, F., Audia, S., Bonnotte, B., Lambotte, O., Noel, N., Fain, O., Moulis, G., Hamidou, M., …, & Mahévas, M. (2023). Prolonged response after TPO-RA discontinuation in primary ITP: results of a prospective multicenter study. Blood. https://doi.org/10.1182/blood.2022018665
Vancouver
Guillet S, Crickx E, Azzaoui I, Chappert P, Boutin E, Viallard JF, et al. Prolonged response after TPO-RA discontinuation in primary ITP: results of a prospective multicenter study. Blood. 2023. doi:10.1182/blood.2022018665
BibTeX
@article{Guillet2023,
author = {Guillet, Stéphanie and Crickx, Etienne and Azzaoui, Imane and Chappert, Pascal and Boutin, Emmanuelle and Viallard, Jean-François and Rivière, Etienne and Gobert, Delphine and Galicier, Lionel and Malphettes, Marion and Cheze, Stéphane and Lefrere, François and Audia, Sylvain and Bonnotte, Bernard and Lambotte, Olivier and Noel, Nicolas and Fain, Olivier and Moulis, Guillaume and Hamidou, Mohamed and Gerfaud-Valentin, Mathieu and Marolleau, Jean-Pierre and Terriou, Louis and Martis, Nihal and Morin, Anne-Sophie and Perlat, Antoinette and Le Gallou, Thomas and Roy-Peaud, Frédérique and Robbins, Ailsa and Lega, Jean-Christophe and Puyade, Matthieu and Comont, Thibault and Limal, Nicolas and Languille, Laetitia and Zarrour, Anissa and Luka, Marine and Menager, Mickael and Belmondo, Thibault and Hue, Sophie and Canoui-Poitrine, Florence and Michel, Marc and Godeau, Bertrand and Mahévas, Matthieu},
title = {Prolonged response after TPO-RA discontinuation in primary ITP: results of a prospective multicenter study},
journal = {Blood},
year = {2023},
doi = {10.1182/blood.2022018665}
}
EUVIMED